Study of Efficacy and Safety of BCD-217 (Anti-CTLA-4 and Anti-PD-1) Followed By BCD-100 (Anti-PD-1) Versus BCD-100 Monotherapy as First-Line Treatment in Patients With Unresectable or Metastatic Melanoma

PHASE2UnknownINTERVENTIONAL
Enrollment

117

Participants

Timeline

Start Date

July 1, 2019

Primary Completion Date

July 31, 2023

Study Completion Date

December 31, 2023

Conditions
MelanomaMelanoma Metastatic
Interventions
BIOLOGICAL

BCD-217

Combination of anti-CTLA-4 and anti-PD-1 monoclonal antibodies, 1mg/kg and 3 mg/mg, respectively, given Q3W as IV infusion for first 4 blinded infusions

BIOLOGICAL

BCD-100

Anti-PD-1 monoclonal antibody, 3 mg/kg, given Q3W as IV infusion for first 4 blinded infusions, after - 1 mg/kg, given Q2W as IV infusion

OTHER

Placebo

Placebo

Trial Locations (23)

123056

Medsi Group of Companies Joint-Stock Company, Moscow

150054

Regional Clinical Oncology Hospital, Yaroslavl

163045

"State Budgetary Healthcare Institution of the Ar-khangelsk Region Arkhangelsk Clinical Oncology Dispensary", Arkhangelsk

183047

Murmansk Regional Clinical Hospital named after P.A. Bayandina, Murmansk

190013

"JSC Modern Medical Technologies", Saint Petersburg

197082

AV Medical Group Limited Liability Company, Saint Petersburg

197758

"Federal State Institution N.N. Petrov National Medical Research Center for Oncology", Saint Petersburg

Saint-Petersburg Petersburg Clinical Scientific and Practical Center for Specialized Types of Medical Care (Oncological), Saint Petersburg

199106

"Federal State Budgetary Educational Institution of Higher Education St. Petersburg State University", Saint Petersburg

220013

"Healthcare Institution Minsk Municipal Clinical Oncolo-gy Dispensary (MMCOD)", Minsk

354057

Clinical Oncologic Dispensary No. 2, Sochi

357500

"LLC New Clinic", Pyatigorsk

443031

"State-financed Health Institution Samara Region Clinical Oncology Dispansary", Samara

454087

"State Budgetary Healthcare Institution Chelyabinsk Regional Clinical Center for Oncology and Nuclear Medicine,", Chelyabinsk

630108

"State Budgetary Healthcare Institution of the Novosi-birsk Region Novosibirsk Regional Clinical Oncolo-gy Dispensary", Novosibirsk

656045

"Territorial State Budgetary Healthcare Institution Altai Territorial Clinical Oncology Dispensary", Barnaul

660133

Krasnoyarsk Regional Clinical Oncological Dispensary named after A.I. Kryzhanovsky, Krasnoyarsk

Unknown

"State Institution N.N. Aleksandrov Republican Research and Practical Center for Oncology and Medical Radiology", The Settlement of Lesnoy

"State public health institution Republican Clinical Oncology Dispensary of the Ministry of Health of the Republic of Tatarstan", Kazan'

"Regional State Budgetary of Healthcare Insti-tution Kostroma Oncology Dispensary", Kostroma

"Russian Cancer Research Center named after N.N. Blokhin of the Ministry of Health of the Russian Federation", Moscow

"State Health Care Institution Moscow City Oncology Hospital № 62 Moscow Health Department", Moscow

"State budget healthcare institution Omsk region Clinical Oncology Dispensary", Omsk

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Biocad

INDUSTRY

NCT03913923 - Study of Efficacy and Safety of BCD-217 (Anti-CTLA-4 and Anti-PD-1) Followed By BCD-100 (Anti-PD-1) Versus BCD-100 Monotherapy as First-Line Treatment in Patients With Unresectable or Metastatic Melanoma | Biotech Hunter | Biotech Hunter